Soligenix Change in Accounts Receivable 2010-2025 | SNGX

Soligenix change in accounts receivable from 2010 to 2025. Change in accounts receivable can be defined as the increase or decrease in accounts receivable for the given period.

Soligenix Change in Accounts Receivable 2010-2025 | SNGX

Soligenix change in accounts receivable from 2010 to 2025. Change in accounts receivable can be defined as the increase or decrease in accounts receivable for the given period.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$247.9B
Amgen (AMGN)$155B
Gilead Sciences (GILD)$141.4B
Vertex Pharmaceuticals (VRTX)$99.8B
Bristol Myers Squibb (BMY)$96.9B
GSK (GSK)$81.3B
CSL (CSLLY)$67.8B
Regeneron Pharmaceuticals (REGN)$62.2B
Alnylam Pharmaceuticals (ALNY)$59.5B
Argenex SE (ARGX)$43.3B
Insmed (INSM)$28.4B
BioNTech SE (BNTX)$24.8B
Royalty Pharma (RPRX)$21B
Biogen (BIIB)$20B
Incyte (INCY)$16.6B
Genmab (GNMSF)$16B
Genmab (GMAB)$15.9B
Illumina (ILMN)$15.3B
Ascendis Pharma (ASND)$11.8B
BioMarin Pharmaceutical (BMRN)$11.3B
Swedish Orphan Biovitrum (BIOVF)$10.9B
QIAGEN (QGEN)$10.7B
Exelixis (EXEL)$10.4B
Moderna (MRNA)$9.8B
Verona Pharma American Depositary Share (VRNA)$9.1B
Exact Sciences (EXAS)$8.8B
Bio-Techne Corp (TECH)$8.8B
Halozyme Therapeutics (HALO)$8.6B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$8.2B